Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Olfactory Receptors: Location and Structure01:03

Olfactory Receptors: Location and Structure

The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olfactory assessment in treatment and survivor groups of pediatric solid malignancies.

Discover oncology·2026
Same author

Effect of Stimulus Duration on the Electrogustometric Threshold.

World journal of otorhinolaryngology - head and neck surgery·2026
Same author

Response to Comments of Pellegrino et al.

Chemical senses·2026
Same author

Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older.

NPJ Parkinson's disease·2025
Same author

Olfactory function is longitudinally associated with semantic fluency in Parkinson's disease: a cohort study.

Journal of neurology·2025
Same author

Odors as cognitive constructs: history of odor classification and attempts to map odor percepts to physical and chemical parameters.

Chemical senses·2025
Same journal

Analysis of strength degradation of coal and rock masses and stability of mined areas under long term immersion environment.

PloS one·2026
Same journal

Biogenic Silver-Selenium nanocomposite with anticancer activity and potent efficacy against vancomycin-resistant Staphylococcus aureus.

PloS one·2026
Same journal

Preparation and physicochemical characterization of a biodegradable chitosan/carboxymethyl cellulose hydrogel synthesized in NaOH/urea medium.

PloS one·2026
Same journal

Action-guilt, survivor-guilt, and depression in combat-related PTSD.

PloS one·2026
Same journal

Explainable machine learning for predicting activities of daily living at discharge in stroke patients: A retrospective study using SHAP interpretability.

PloS one·2026
Same journal

Deep learning based two-way feature depiction model for brain tumor detection.

PloS one·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Olfactory Assays for Mouse Models of Neurodegenerative Disease
07:27

Olfactory Assays for Mouse Models of Neurodegenerative Disease

Published on: August 25, 2014

Profound olfactory dysfunction in myasthenia gravis.

Fidias E Leon-Sarmiento1, Edgardo A Bayona, Jaime Bayona-Prieto

  • 1Smell and Taste Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. feleones@gmail.com

Plos One
|October 20, 2012
PubMed
Summary
This summary is machine-generated.

Patients with myasthenia gravis (MG) experience significant olfactory dysfunction, a profound loss of smell. This deficit is linked to the autoimmune disease, not general cognitive issues or sniffing difficulties.

More Related Videos

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

A Free-breathing fMRI Method to Study Human Olfactory Function
10:42

A Free-breathing fMRI Method to Study Human Olfactory Function

Published on: July 30, 2017

Related Experiment Videos

Last Updated: May 17, 2026

Olfactory Assays for Mouse Models of Neurodegenerative Disease
07:27

Olfactory Assays for Mouse Models of Neurodegenerative Disease

Published on: August 25, 2014

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

A Free-breathing fMRI Method to Study Human Olfactory Function
10:42

A Free-breathing fMRI Method to Study Human Olfactory Function

Published on: July 30, 2017

Area of Science:

  • Neurology
  • Immunology
  • Sensory Neuroscience

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder primarily affecting the neuromuscular junction.
  • While known for neuromuscular symptoms, potential central nervous system impacts, including sensory deficits, are less understood.

Purpose of the Study:

  • To investigate olfactory function in patients with myasthenia gravis.
  • To differentiate MG-related olfactory deficits from those caused by general cognitive impairment or neuromuscular symptoms.

Main Methods:

  • Utilized the University of Pennsylvania Smell Identification Test (UPSIT) to assess olfactory function.
  • Employed the Picture Identification Test (PIT) to control for non-olfactory cognitive confounds.
  • Compared olfactory test results between MG patients, healthy controls, and polymyositis patients.

Main Results:

  • Myasthenia gravis patients demonstrated significantly lower UPSIT scores compared to healthy controls and polymyositis patients.
  • Olfactory deficits in MG patients were not attributable to difficulties in sniffing or general cognitive impairment.
  • No correlation was found between olfactory function and disease-specific factors like thymectomy or antibody levels.

Conclusions:

  • Myasthenia gravis is associated with a profound olfactory deficit, comparable to that seen in some neurodegenerative diseases.
  • The findings suggest a potential central nervous system involvement in MG impacting olfactory pathways.
  • Further research is warranted to elucidate the mechanisms underlying MG-associated olfactory dysfunction.